Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across three cohorts in resectable locally advanced HNSCC.
News|Articles|March 26, 2026
Multidisciplinary Breast Cancer Conversations Raise Insightful Questions for Clinical Practice Applications
Author(s)Ashling Wahner
Fact checked by: Riley Kandel
Oncology experts ask and answer multidisciplinary questions based on presentations from the 43rd Annual Miami Breast Cancer Conference.
Advertisement
Advertisement
The
Related to this article
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Advertisement
Advertisement